Repligen Corporation
NASDAQ:RGENMedical - Instruments & Supplies
-$3.66 today
- Market cap
- $11.04B
- Beta
- 1.08
- P/E (TTM)
- 142.4
- EPS (TTM)
- $0.91
Volume 1.30M
Average 1.08M
RGEN Research & Development
Spending on developing new products, technologies, and improvements to existing offerings.
Repligen CorporationNASDAQ: RGEN
Research & Development · Q2 FY2026 · quarter ended Jun 2026
Research & development grows, but more slowly than its trailing trend
Q2 FY2026 research & development of $14.42M rose 3.3% year over year, behind the +14.4% change in trailing-twelve-month research & development. Sequentially, it fell 0.3% from the prior quarter. Over 3 fiscal years it compounded at +7.2% a year.
Context
- Research & development amounted to 7.3% of revenue in FY2025, up 0.5 pp from a year earlier.
- Research & development increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth recovers from +3.3% toward the trailing-twelve-month pace of +14.4%.
Sources:Income StatementText generated from reported figures; not investment advice.
Research & Development history
USD · from the income statement
- Latest · FY2025
- 54.18M USD
- Year-over-year change
- +25.4%
- 4-year CAGR
- +12.1%
| Period | Period end | Research & Development | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 54.18M | +25.4% |
| FY2024 | 2024-12-31 | 43.2M | +1.1% |
| FY2023 | 2023-12-31 | 42.72M | -2.8% |
| FY2022 | 2022-12-31 | 43.94M | +28.2% |
| FY2021 | 2021-12-31 | 34.27M | — |
Research & Development vs competitors
How RGEN compares with its peers on the latest reported figures
- RGEN's LTM Jun 2026 research & development of $55.23M is the 6th highest of the 9 companies compared; the peer median is $145.77M.
- Its year-over-year change of +14.4% is the highest of 8, against a peer median of +5.5%.
- Research & development amounts to 7.0% of revenue for RGEN, versus a peer median of 8.0%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Sep 2026 | $1.41B | -0.7% | -1.7% | 3.0% | |
| LTM Jul 2026 | $485M | +8.5% | -0.9% | 6.6% | |
| LTM Jun 2026 | $261.1M | -14.3% | +0.0% | 10.1% | |
| LTM Jun 2026 | $194.67M | +5.5% | -0.4% | 9.3% | |
| LTM Sep 2026 | $96.87M | -3.0% | +0.8% | 7.9% | |
| LTM Jun 2026 | $55.23M | +14.4% | +7.2% | 7.0% | |
| LTM Jun 2026 | $21.15M | +13.2% | +8.3% | 10.1% | |
| LTM Mar 2026 | $8.14M | +5.5% | -20.0% | 8.2% | |
| LTM Jun 2026 | $0 | — | — | 0.0% | |
| Peer median (excluding RGEN) | $145.77M | +5.5% | -0.4% | 8.0% | |
Competitors are the stored peer set for RGEN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 670.53M | 801.54M | 632.36M | 634.44M | 738.26M |
| Cost of Revenue | 279.28M | 345.83M | 353.92M | 359.79M | 390.63M |
| Gross Profit | 391.25M | 455.71M | 278.44M | 274.65M | 347.62M |
| Gross Margin | 58.3% | 56.9% | 44.0% | 43.3% | 47.1% |
| Research & Development | 34.27M | 43.94M | 42.72M | 43.2M | 54.18M |
| Selling, General & Admin | 183.87M | 215.83M | 218.58M | 263.37M | 290.51M |
| Operating Expenses | 224.01M | 231.04M | 230.74M | 309.76M | 288.05M |
| Depreciation & Amortization | 38.45M | 57.01M | 86.11M | 86.56M | 96.96M |
| EBITDA | 203.27M | 277.31M | 145.32M | 80.26M | 182.51M |
| EBITDA Margin | 30.3% | 34.6% | 23.0% | 12.7% | 24.7% |
| Operating Income | 167.25M | 224.67M | 47.7M | (35.11M) | 59.58M |
| Operating Margin | 24.9% | 28.0% | 7.5% | -5.5% | 8.1% |
| Interest Income | 176K | 6.98M | 0 | 0 | 27.57M |
| Interest Expense | 12.71M | 2.98M | 10.03M | 22.57M | 23.17M |
| Other Income / Expenses | (13.71M) | (5.53M) | 9M | 8.08M | 2.81M |
| Income Before Tax | 153.54M | 219.14M | 56.71M | (27.04M) | 62.38M |
| Pre-Tax Margin | 22.9% | 27.3% | 9.0% | -4.3% | 8.5% |
| Income Tax Expense | 25.25M | 33.18M | 21.11M | (1.52M) | 13.49M |
| Net Income | 128.29M | 185.96M | 35.6M | (25.51M) | 48.89M |
| Net Margin | 19.1% | 23.2% | 5.6% | -4.0% | 6.6% |
| EPS (Basic) | 2.33 | 3.35 | 0.64 | (0.46) | 0.87 |
| EPS (Diluted) | 2.24 | 3.24 | 0.63 | (0.46) | 0.86 |
| Weighted Avg Shares | 55.02M | 55.46M | 55.72M | 55.94M | 56.23M |
| Weighted Avg Shares (Diluted) | 57.26M | 57.46M | 56.38M | 55.94M | 56.56M |
Repligen Corporation
NASDAQ:RGEN
Intrinsic Alpha fair value
Locked
Current Price
$172.67
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.